Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Cytokinetics (CYTK) Accumulated Depreciation & Amortization (2016 - 2025)

Cytokinetics (CYTK) has disclosed Accumulated Depreciation & Amortization for 13 consecutive years, with $28.3 million as the latest value for Q4 2023.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 65.84% to $28.3 million in Q4 2023 year-over-year; TTM through Dec 2023 was $28.3 million, a 65.84% increase, with the full-year FY2023 number at $28.3 million, up 65.84% from a year prior.
  • Accumulated Depreciation & Amortization was $28.3 million for Q4 2023 at Cytokinetics, up from $17.1 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $28.3 million in Q4 2023 to a low of $16.2 million in Q4 2021.
  • A 5-year average of $22.1 million and a median of $24.2 million in 2019 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: tumbled 34.3% in 2021, then surged 65.84% in 2023.
  • Cytokinetics' Accumulated Depreciation & Amortization stood at $24.2 million in 2019, then increased by 1.84% to $24.6 million in 2020, then crashed by 34.3% to $16.2 million in 2021, then rose by 5.59% to $17.1 million in 2022, then skyrocketed by 65.84% to $28.3 million in 2023.
  • Per Business Quant, the three most recent readings for CYTK's Accumulated Depreciation & Amortization are $28.3 million (Q4 2023), $17.1 million (Q4 2022), and $16.2 million (Q4 2021).